Navigation Links
Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Date:5/8/2013

ANAHEIM, Calif., May 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.  


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
2. Questcor Pharmaceuticals Expands Repurchase Program
3. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
11. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... , ... Cambridge Semantics , the leading provider of Big Data management ... and Expo in Boston May 23-25 with a featured speaker and solution demos ... Lake is also a finalist for the Best of Show award. , James LaPointe, ...
(Date:5/22/2017)... ... May 22, 2017 , ... Cancer diagnostics and pathology workflow ... at the Association for Pathology Informatics Annual Summit at the Wyndham ... its Cancer Diagnostic Cockpit and Consultation Portal, Inspirata will present research it led ...
(Date:5/19/2017)... ... 19, 2017 , ... The University City Science Center is ... for commercialization, and who are affiliated with the 21 partner academic and research ... now in its tenth round, is the first multi-institutional proof-of-concept program for the ...
(Date:5/18/2017)... ... May 17, 2017 , ... NDA Partners Chairman Carl Peck, MD ... Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health, has ... and Cardinal Health, he was former Chief Operating Officer at Anaborex, Senior VP and ...
Breaking Biology Technology:
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/23/2017)... DUBLIN , Mar. 23, 2017 Research ... Anti-Theft System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 8.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):